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Abstract 
NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine 
potency and safety testing methods, and to identify opportunities to advance new and improved methods that can further reduce, 
refine, and replace animal use. This report addresses methods and strategies identified by workshop participants for replacement
of animals used for potency testing of human vaccines. Vaccines considered to have the highest priority for future efforts were
(1) vaccines for which antigen quantification methods are already developed but not validated, (2) vaccines/components that 
require the largest number of animals, (3) vaccines that require an in vivo challenge test, and (4) vaccines with in vivo tests that 
are highly variable and cause a significant number of invalid tests. Vaccine potency tests identified as the highest priorities for 
replacement were those for diphtheria and tetanus, pertussis (whole cell and acellular), rabies, anthrax, polio vaccine (inactivated)
and complex combination vaccines based on DT or DTwP/aP. Research into understanding the precise mechanism of protection 
afforded by vaccines and the identification of clinically relevant immunological markers are needed to facilitate the successful
implementation of in vitro testing alternatives. This report also identifies several priority human vaccines and associated research 
objectives that are necessary to successfully implement in vitro vaccine potency testing alternatives. 
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1. Introduction 
Vaccines contribute to improved animal and human health and welfare by preventing and controlling infectious 
diseases. However, testing necessary to ensure vaccine effectiveness and safety can involve large numbers of 
animals and significant pain and distress. Accordingly, the U.S. Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM) and the U.S. National Toxicology Program Interagency Center for 
the Evaluation of Alternative Toxicological Methods (NICEATM) recently identified vaccine potency and safety 
testing as one of their four highest priorities [1].  
ICCVAM is an interagency committee of Federal agencies that is charged by law with evaluating new, revised, 
and alternative test methods with regulatory applicability. ICCVAM members represent 15 U.S. Federal regulatory 
and research agencies that require, use, generate, or disseminate safety testing data. These include the Department of 
Agriculture (USDA), which regulates veterinary vaccines, and the Food and Drug Administration (FDA), which 
regulates human vaccines. ICCVAM is a permanent interagency committee of the National Institute of 
Environmental Health Sciences (NIEHS) under NICEATM. NICEATM administers ICCVAM, provides scientific 
and operational support for ICCVAM-related activities, and conducts international validation studies on promising 
new safety testing methods. NICEATM and ICCVAM serve a critical public health role in translating research 
advances from the bench into standardized safety testing methods that can be used in regulatory practice to prevent 
disease and injury. 
To promote and advance the development and use of scientifically valid alternative methods for human and 
veterinary vaccine testing, NICEATM and ICCVAM organized the International Workshop on Alternative Methods 
to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and 
Future Directions. The workshop was held at the National Institutes of Health in Bethesda, Maryland, on September 
14–16, 2010. It was organized in conjunction with the European Centre for the Validation of Alternative Methods 
(ECVAM), the Japanese Center for the Validation of Alternative Methods (JaCVAM), and Health Canada. 
The workshop addressed the state of the science of human and veterinary vaccine potency and safety testing. 
Participants developed recommendations for future progress in three major areas: (1) in vitro replacement methods 
for potency testing; (2) reduction and refinement methods for potency testing; and (3) reduction, refinement, and 
replacement methods for vaccine safety testing [2]. Reports were prepared for each of the three topics for human 
vaccines and for each of the three topics for veterinary vaccines [3, 4, 5, 6, 7, 8]. This report addresses methods and 
strategies for the replacement of animal use for potency testing of human vaccines.  
2. Goals and organization of the workshop 
The goals of the international workshop were to (1) identify and promote the implementation of currently 
available and accepted alternative methods that can reduce, refine, and replace the use of animals in human and 
veterinary vaccine potency and safety testing; (2) review the state of the science of alternative methods and identify 
knowledge and data gaps that need to be addressed; and (3) identify and prioritize research, development, and 
validation efforts needed to address these gaps in order to advance alternative methods that will also ensure 
continued protection of human and animal health. 
The workshop was organized with four plenary sessions and three breakout group sessions. In the breakout 
sessions, workshop participants: 
x Identified criteria to prioritize vaccine potency and safety tests for future alternative test method development and 
identified high priorities using these criteria 
x Reviewed the current state of the science of alternative methods and discussed ways to promote the 
implementation of available methods 
Open access under CC BY-NC-ND license.
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x Identified knowledge and data gaps that need to be addressed 
x Identified and prioritized research, development, and validation efforts needed to address these gaps in order to 
advance alternative methods while ensuring continued protection of human and animal health 
The workshop opened with a plenary session in which expert scientists and regulatory authorities from the United 
States, Europe, Japan, and Canada outlined the importance of vaccines to human and animal health [9, 10] and 
described national and international regulatory testing requirements for human and veterinary vaccines [2, 11, 12, 
13, 14, 15, 16]. Authorities emphasized that, following the regulatory approval of a vaccine, testing is required to 
ensure that each subsequent production lot is pure, safe, and sufficiently potent to generate a protective immune 
response in people or animals [11, 12]. 
The second plenary session addressed methods that have been accepted and methods that are in development that 
do not require the use of animals for assessing the potency of vaccines [17, 18, 19, 20]. This was followed by 
breakout sessions to discuss the state of the science and recommendations for future progress for in vitro potency 
tests for human and veterinary vaccines. Workshop recommendations to advance the use and development of 
alternative methods that can replace animals for the potency testing of human vaccines are provided in this paper, 
while the report on replacement of animals for veterinary vaccines is available elsewhere in these proceedings [4]. 
The third plenary session addressed (1) potency testing methods that refine procedures to avoid or lessen pain and 
distress by incorporating earlier humane endpoints or by using antibody quantification tests instead of challenge 
tests and (2) methods and approaches that reduce the number of animals required for each test [21, 22, 23, 24, 25, 
26, 27]. Breakout groups then discussed the state of the science and developed recommendations for future progress. 
Workshop recommendations to advance the use and development of alternative methods that can reduce and refine 
animal use for potency testing of human vaccines [5] and veterinary vaccines [6] are available in the respective 
publications in these proceedings. 
The final plenary session addressed methods and approaches for reducing, refining, and replacing animal use to 
assess the safety of serial production lots of human and veterinary vaccines [11, 28, 29, 30]. Breakout groups then 
discussed the state of the science and developed recommendations for advancing alternative methods for vaccine 
safety testing. Workshop recommendations to advance the use and development of alternative methods for safety 
testing of human vaccines [7] and veterinary vaccines [8] are available in the respective publications in these 
proceedings.
3. Requirements for human vaccine potency testing
Human vaccines save lives, prevent disease and morbidity, and represent a critical tool for successful and cost-
saving health interventions [10]. For example, for each U.S. birth cohort that receives a series of seven vaccines that 
protect against infectious diseases including diphtheria, tetanus, pertussis, measles, mumps, rubella, and polio, an 
estimated 14 million disease episodes and 33,000 premature deaths are prevented. These vaccinations are estimated 
to save 43 billion dollars in medical and societal costs [10, 31]. Because of the number of animals used annually for 
the release of human vaccines, many regulatory agencies actively encourage the evaluation, development, and 
implementation of novel approaches that reduce, refine, and replace (3Rs) the use of animals in vaccine safety and 
potency product release testing [11, 19].  
The U.S. Public Health Service Act [32] and certain sections of the U.S. Food, Drug and Cosmetic Act [33] give 
the FDA the authority to regulate human vaccines. Section 351 of the Public Health Service Act states that the 
approval of a biologics license is based on the demonstration of product safety, purity, and potency and assurance 
that the facility for manufacture, processing, and packaging meets the standards to ensure that any product released 
for distribution is safe, pure, and potent. The regulatory definitions of safety, purity, and potency are detailed in Title 
21 of the U.S. Code of Federal Regulations, and testing methodology and validation must be included in the 
biologics license application (BLA) [34]. Safety and potency testing may be performed on the final bulk sample or 
final container sample and may consist of either in vivo or in vitro tests or both. Post-licensing changes to potency or 
safety tests require a supplement to the license with adequate rationale and data to support the alternative method 
(potency or safety) or to support the demonstration of lack of need for a particular test (safety).  
Current human vaccines consist of: 
x Live viruses 
x Modified live (attenuated) viruses and bacteria 
19Richard McFarland et al. / Procedia in Vaccinology 5 (2011) 16 – 32 19 Richard McFarland et al. /  Procedia in Vaccinology  5 ( 2011 )  16 – 32 
x Inactivated (killed) viruses and bacteria 
x Toxoids (chemically inactivated toxins) 
x Polysaccharides
The general types of potency tests employed by vaccine manufacturers include (1) titration of live organisms (in 
vitro, but occasionally in vivo); (2) in vitro assays such as enzyme-linked immunosorbent assays (ELISAs) or other 
antigen quantification methods; (3) in vivo methods involving immunization of small laboratory animals (e.g., 
guinea pigs, rats, mice) followed by challenge with toxin/virus/bacteria or titration of immune sera to measure the 
antibody response [19]. In vitro potency testing is used for live, attenuated vaccines but is not commonly used for 
inactivated vaccines [35]. 
The Center for Biologics Evaluation and Research (CBER) has an active research program that evaluates, 
develops, and integrates novel scientific technologies for use in product regulation. The CBER program includes the 
development and analysis of approaches that reduce, refine, and replace the use of animals. CBER encourages the 
development of these alternative methods for vaccine safety and potency testing with appropriate relevance, 
supporting data, and test method validation. Reduction and refinement approaches can be applied to all serological 
or vaccination–challenge methods that use animals to determine the potency of a human vaccine. 
4. Prioritizing vaccine potency tests for future research, development, and validation activities 
The current potency testing methods for several human vaccines still utilize animals (Table 1), and the 
development of alternative assays for these products would significantly reduce the number of animals used for 
testing and benefit animal welfare. To identify human vaccines that should have priority for further development 
and validation of in vitro replacement tests, criteria for prioritization were established at this workshop. Workshop 
participants agreed on the following vaccine prioritization criteria for development of in vitro potency tests: 
x Vaccines for which antigen quantification methods are already developed but not validated for routine use 
x Vaccines/components that require the largest number of animals 
x Vaccines that require an in vivo challenge test 
x Vaccines with in vivo tests that are highly variable and cause a significant number of invalid tests 
x Vaccines for which the relationship between antigen quantity and potency are well understood 
x Combined vaccines (recognizing that their complexity may make successful replacement more difficult than 
single-component vaccines) 
x Vaccines that have a well-defined and understood mode of action or known target 
x Vaccines for which the manufacturing process is well understood and consistent 
Based upon the key criteria described above, workshop participants identified the following vaccines as the 
highest priorities for additional research, development, and validation efforts: 
x Diphtheria and tetanus toxoid vaccines 
x Whole cell and acellular pertussis vaccines 
x Rabies vaccines 
x Anthrax vaccines 
x Complex combination vaccines 
x Inactivated polio vaccines 
Diphtheria and tetanus toxoids were considered the highest priorities because the current potency tests require 
large numbers of animals. Rabies and anthrax vaccines were identified as priorities because the tests also require 
large numbers of animals and may involve significant pain and distress. In addition, the vaccine-challenge test for 
these vaccines requires the use of live virus, toxin, or bacteria that pose significant safety risks for laboratory 
technicians. The current in vivo potency test for inactivated rabies vaccines is also known to be highly variable [19] 
and produces a significant number of invalid tests.  
Finally, the use of antigen quantification methods for those vaccines for which the protective antigen is already 
known was considered to be a high priority for validation and further development. As shown in Table 1,
serological methods are currently in development or have been approved for use by specific regulatory authorities 
for many of these high-priority vaccines. The availability of these refinement methods indicates that they should 
therefore aid in the development of replacement methods based on in vitro antigen quantification [36]. 
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Table 1. Examples of human vaccine potency tests that reduce or refine the use of animals 
Vaccine Product 3Rs Alternative References For Alternative Methods 
Traditional Test 
Procedure for which the 
Alternative Method is 
Applicable
References for 
Traditional Methods 
Bacterins and Toxoids 
Tetanus toxoid vaccine 
and tetanus component 
in combined vaccines 
(Clostridium tetani)
Single-dilution immunization 
and serologyb, c –in vitro
toxin-binding inhibition 
(ToBIb, c), indirect ELISAb, c,
Humane Endpoint - toxin-
injected hind leg paresisb, c
Ph. Eur. 2.7.8. Assay of 
tetanus vaccine (adsorbed) 
[37];  
WHO TRS 927, Annex 5, 
2003 [39] 
Guinea pig or mouse lethal 
challenge test 
U.S. Minimum 
Requirements, 1952 
[38]; 
Diphtheria toxoid 
vaccine and diphtheria 
component in combined 
vaccines
(Corynebacterium
diphtheriae)
Single-dilution immunization 
and Serologyb, c – ELISA or 
Vero Cell Assayb, c ; Humane 
endpoint - erythema score 
following intradermal 
challenge in guinea pigsb, c
Ph. Eur. 2.7.6 Assay of 
diphtheria vaccine 
(adsorbed) [40]; WHO 
TRS 927, Annex 5, 2003 
[39] 
Guinea pig lethal 
challenge test 
U.S. Minimum 
Requirements, 1947 
[41]; 
Acellular pertussis 
vaccine: whooping 
cough
(Bordetella pertussis)
Immunization (mice) and 
serologya, b, c 
ELISA
Ph. Eur. Monograph 1356 
[42] and 1595 [43];  
Japanese Minimum 
Requirements for 
Biological Products, 
2006 [44]; WHO TRS 
878, Annex 2, 1998 [45] 
Mouse serology testc, d 
Viral Vaccines 
Rabies vaccine; 
(Lyssavirus rabies)
Immunization (mice) and 
Serologyb, c, Humane 
Endpoints - convulsions, 
paralysis, paresisa, b, c 
Ph. Eur. Monograph 216 
[46]; WHO TRS 941, 
Annex 2, 2007 [47] 
Mouse multiple-dilution 
lethal challenge test
Seligmann 1973 [48] 
aAccepted by U.S. regulatory authorities.
bPublished in the European Pharmacopoeia.  
cWHO Technical Report Series number and year of publication.  
dCurrent test in Asia.
5. Human vaccine potency testing: non-animal replacement alternative methods 
Currently, some human vaccines do not require the use of animals because in vitro methods have been developed 
that quantify the presence of the protective antigen. These so-called antigen quantification methods are based on 
binding of key protective antigens in the vaccine batch to specific antibodies using in vitro immunoassays. At the 
present time, these methods represent the most promising in vitro approaches for the replacement of animals used in 
vaccine potency testing. It is important to note, however, that in vitro antigen quantification methods only measure 
antigen quantity and do not necessarily reflect biological activity. Another limitation of these methods is the 
requirement for adjuvant removal from the product before testing. Therefore, it is necessary to also demonstrate that 
the process of adjuvant removal does not affect recovery and/or integrity of the antigen, which could interfere with 
its detection in the assay [35].  
5.1. State of the science 
To date, in vitro tests have been successfully implemented (regulatory acceptance) for only a few products. These 
include hepatitis A/B vaccines, inactivated polio vaccine, polysaccharide and polysaccharide conjugate vaccines, 
and human papillomavirus vaccine (Table 2). For the recombinant hepatitis B vaccine, two types of in vitro
immunoassays have been developed as alternatives to the mouse immunogenicity test. The first is based on the 
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direct determination of the hepatitis B surface antigen (HbsAg), while the other is based on the neutralization of 
HbsAg and subsequent detection of remaining anti-HbsAg antibodies in an ELISA [35, 49, 50].  
Table 2. Examples of human vaccine potency tests that replace the use of animals 
Vaccine Product Available In VitroAlternative Method 
References
for Alternative Methods
Traditional Test Procedure 
for which the Alternative 
Method is Applicable 
Viral vaccines 
Hepatitis A vaccine 
(hepatitis A virus) 
Antigen quantificationa, b Ph. Eur. Monograph 1935 [51] and general 
method 2.7.1 [52]; WHO TRS 858, 1995 [53] 
Mouse serologyc
Hepatitis B vaccine 
(hepatitis B virus) 
Antigen quantificationa, b Ph. Eur. Monograph 1056 [54] and ch 2.7.15 
[55]; WHO TRS 889, 1999 [56] 
Mouse serologyc
Inactivated polio vaccine 
(poliovirus) 
Antigen quantificationa, b Ph. Eur. Monograph 214 [57] and general 
method 2.7.1 [52]; WHO TRS 910, 2002 [58] 
Rat serologyd
Human papillomavirus 
vaccine
Antigen quantificationa, b WHO (in press) Mouse serology 
Polysaccharide and 
polysaccharide conjugate 
vaccines
NAe - Antigen quantificationa, b, f
aPublished in the European Pharmacopoeia.  
bWHO Technical Report Series. 
cNo mouse test in European Pharmacopoeia.  
dNot for routine lot release (Ph. Eur.). 
eTraditional method is antigen quantification  
fAccepted by U.S. regulatory authorities 
Perhaps the most critical need for a valid alternative for potency testing is in the area of rabies vaccines. The 
traditional method for inactivated rabies vaccine potency testing is a multiple-dilution vaccination challenge test in 
mice. This test, commonly referred to as the NIH test, because of the origin of its development (the National 
Institutes of Health), is based on the relative proportion of animals protected from rabies in groups receiving the test 
vaccine compared to those immunized with a reference vaccine. The need for an alternative test is critical because 
the traditional potency test requires large numbers of animals that experience unrelieved pain and distress. 
Approximately half of the test animals die or develop acute signs of rabies (e.g., convulsions, paresis, paralysis). 
The inherent variability of this assay contributes to a high number of invalid assays, which leads to further use of 
animals for repeat testing [59]. The potential exposure of laboratory technicians to biohazardous materials during 
testing is also an important consideration.  
In recent years, national and international regulatory agencies have introduced one or more 3Rs initiatives for 
rabies vaccine potency testing that can be seen as significant improvements to the welfare of test animals. These 
include (1) a single-dilution assay, which reduces the number of dilutions (and therefore animals) for the test 
(reduction); (2) routine use of humane endpoints to allow earlier study termination (refinement); (3) a serological 
assay that obviates the need for in vivo challenge with rabies virus (refinement).  
There are antigen quantification methods available that may one day eliminate the need for an in vivo potency 
test (replacement), leading to a significant reduction in the use of animals for testing. Several types of in vitro
ELISA procedures for rabies vaccines have been developed during the past few years, taking advantage of advances 
in defining the neutralizing epitopes [59, 60, 61]. While these assays would confer distinct advantages over in vivo
test methods (e.g., no animals required, faster, less costly), limitations that have impeded their development and 
implementation include the following: (1) they are not universally applicable to all vaccine strains, (2) they cannot 
be used in combination with adjuvants, and (3) they do not correlate well with the in vivo challenge test [35, 59]. 
Clear correlations have yet to be demonstrated among the amount of antigen required to induce a protective immune 
response in animals, the amount of antigen measured using alternative in vitro assays, and the immune response in 
human vaccines [19]. Therefore, it is difficult to correlate potency defined by protection in animals versus potency 
defined by alternative methods [19, 35]. However, further studies targeted toward the potential usefulness of ELISA 
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procedures for rabies vaccine potency testing are ongoing [19]. These initiatives represent critical first steps toward 
developing a scientifically valid alternative replacement method for potency testing of rabies vaccines. It is of note 
that the European Pharmacopoeia has now issued a draft proposal for comments for the use of antibody 
quantification for lot release of rabies vaccines for veterinary use, subject to product-specific validation [62]. 
5.2. Knowledge gaps and priority research, development, and validation activities 
With the identification of the highest-priority vaccines for replacement potency assay development, the 
knowledge and data gaps that have previously prevented use of non-animal potency assays must be addressed. A 
thorough understanding of the pathogenesis of an infectious disease and associated protective mechanisms is 
necessary to accurately identify the specific antigen or key epitope responsible for eliciting a protective immune 
response. Once a clinically relevant antigen/epitope is identified, further studies are required to fully understand its 
role in protection and how the antigen in the vaccine may be affected by the vaccine manufacturing process (e.g., 
epitope modification due to detoxification and absorption to adjuvant) and how this process may alter how the 
vaccine is presented to the immune system and how it is processed in the target species. Studies can then be 
conducted to determine the structure and stability of antigen so that immunological markers can ultimately be 
identified to measure the immune response in the target species. 
For some vaccine antigens, the mechanism of protection is well understood, and the antigens are well 
characterized. This is the case for diphtheria and tetanus antigens. Despite the complexity of the detoxification and 
production processes involved in manufacturing these toxoid vaccines, methods are available for in vitro
quantification of the antigen in the final product [36, 63]. However, the amount of antigen detected using an in vitro
method and the biological activity (in vivo potency) may depend on additional factors: for example, in certain 
combination vaccines containing tetanus toxoid as an active ingredient and Hib polysaccharide conjugated to tetanus 
toxoid (e.g. DTwP + Hib-TT [63] and an experimental DTaP-IPV + Hib- vaccine [64]) tetanus potency measured 
using the in vivo method was increased relative to the potency of a vaccine which did not contain the Hib-TT 
component due to the presence of the carrier protein. In such cases the amount of tetanus toxoid detected by an in 
vitro binding assay may not be different because the in vitro assay cannot detect the conjugated tetanus toxoid [62]. 
In such circumstances this may be an additional challenge to address during replacement of an in vivo test with an in 
vitro detection method. 
The availability of selected animal disease models can facilitate identification of immunological markers, which 
will then aid in developing in vitro tests. For example, vaccines containing recombinant Papillomavirus virus-like 
particles (VLPs) have been used to control disease in cows, dogs, and rabbits. These successes provided the basis for 
subsequent licensure of a bivalent and quadravalent human papilloma virus (HPV) vaccine to control cervical cancer 
in humans [66].  
Ready access to relevant information plays a key role in the development, validation, and subsequent 
implementation of in vitro vaccine potency test methods. Ideally, manufacturers and regulatory authorities should 
frequently interact and share information in order to avoid duplicating efforts in defining procedures used to validate 
alternative in vitro tests. However, proprietary issues may limit the dissemination of information to outside 
stakeholders. Increased engagement by academic researchers could provide a means through which information is 
publicized through various vehicles such as journal publications, workshops, and scientific/professional society 
meetings.  
Any strategy for the development of alternative replacement methods must be based on a step-by-step approach. 
Ideally, the definitive potency assay (in vivo or in vitro) should be developed before licensing to eliminate the need 
for parallel in vivo testing for licensing or complex comparability protocols.  
Finally, there is a clear need to differentiate between tests limited to measure the amount of antigen and 
additional tests for demonstrating manufacturing consistency, as a single test only assessing antigen quantity is 
unlikely to provide all the required information. Changes in the structural properties of the product that affect its 
efficacy may not be detected by some tests. Therefore, an additional priority would be to determine the ability of in 
vitro antigen quantification test in predicting product molecular stability and/or biological activity. 
Significant time and resources are required for each of the above priority vaccines because of (1) the complexities 
associated with moving from an in vivo test method to one that does not use animals and (2) the significant costs 
associated with the research, development, and validation of in vitro vaccine potency test methods [18, 20]. 
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Therefore, workshop participants strongly encourage early and frequent interactions with regulators throughout this 
process to maximize the likelihood of a final design that will be accepted by regulatory authorities and to avoid any 
unnecessary delays. 
6. Achieving broader acceptance and use of currently available non-animal replacement methods for human 
vaccine potency testing 
Workshop participants agreed that broader access to all relevant information describing successfully 
implemented alternative potency testing methods would have an obvious impact on expanding their use and 
acceptance. For example, open online access to the United States Pharmacopeia (USP) and European 
Pharmacopoeia (Ph. Eur.) monographs would greatly facilitate the dissemination of methods and procedures that 
have been implemented for use by regulators in various regions. Manufacturers are also encouraged to frequently 
consult with the relevant regulatory authorities regarding their planned study design and how best to incorporate 
alternative methods into vaccine potency testing (i.e., product-specific validation). All workshop participants 
recognized the need for harmonization during the vaccine development phase and noted that any guidelines that 
would standardize an approach, or a roadmap on how to transition from in vivo to in vitro testing, would be helpful. 
Collaborative interlaboratory studies involving both national control authorities and supranational organizations, 
such as the European Directorate for the Quality of Medicines (EDQM; Ph. Eur.) and WHO, could accomplish this.  
Workshop participants recognized that the significant costs and the lack of available funding associated with 
additional research, development, and validation efforts of in vitro vaccine potency test methods are the primary 
barriers to progress. More specifically, they agreed that concerns associated with rabies vaccine antigen 
quantification methods need to be addressed. This includes increasing the availability of reference standards and 
antisera for the various rabies strains, as well as maintaining a consistent source of antisera (or, preferably, a set of 
nonproprietary monoclonal antibodies). Workshop participants identified the following issues that would aid in 
facilitating the broader acceptance of alternative methods:  
x Establishment of readily available and/or nonproprietary reference standards 
x Sharing of resources, including key reagents and assay procedures 
x Educational outreach in bioethics and training in the conduct of 3Rs assays 
x International harmonization of requirements for acceptable test methods 
7. Replacement methods: extrapolating veterinary vaccine potency testing to human vaccines and vice versa 
Significant differences exist between human and veterinary vaccine production and formulation, most notably the 
presence of complex adjuvants or adjuvant combinations in veterinary vaccines. Extrapolating results from in vitro
methods developed for a veterinary vaccine to the similar human vaccine is often not possible. For example, human 
influenza vaccines are often not adjuvanted, while veterinary influenza vaccines (e.g., avian, swine) may contain 
mineral oil or other more complex adjuvants. Use of adjuvants may also result in significantly lower antigen content 
in veterinary vaccines compared to that present in nonadjuvanted human vaccines. Veterinary vaccines are often not 
as well characterized as the corresponding human vaccines and are typically composed of complex mixtures that 
include antigens derived from the whole cell, cell lysates, or cell culture supernatants. Each of these variables could 
influence both safety and potency of the vaccine product.
Table 3 provides a list of veterinary vaccines for which antigen quantification methods have been accepted for 
use by some regulatory authorities.  
Taking into account these significant differences between human and veterinary vaccines, workshop participants 
discussed ways to extrapolate alternative potency testing results from veterinary to human vaccines. Increased 
interaction and communication between global regulatory agencies, research institutions, and vaccine manufacturers 
was recognized as the critical first step in this process. One suggestion was to develop an interagency task force to 
deal with specific issues relevant to both human and veterinary medicine. For example, the increased complexity of 
adjuvants in certain veterinary vaccines has resulted in a better understanding of adjuvant/antigen interactions, 
which may be useful to human vaccine manufacturers as additional adjuvants are considered for approval in their 
products. Conversely, antigen quantification methods that are currently available for human rabies vaccines for in-
process control (WHO technical guidelines) may be useful to veterinary rabies vaccine manufacturers. 
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Table 3. Examples of veterinary vaccine potency assays that incorporate in vitro non-animal methods 
Vaccine Product 
(Disease) 3Rs Alternative
References for 
Alternative Methods
Traditional Test 
Procedure for 
Which the 
Alternative Method 
is Applicable 
References for 
Traditional
Methods 
Modified Live Bacterial Vaccines 
Brucella abortusa
(cattle brucellosis) 
In vitro titration method 
determining colony-forming 
units (tryptose agar) 
USDA SAM 600 (2009)d ; 
9 CFR 113.65 [67]
- -
Erysipelothrix
rhusiopathiaea
(swine erysipelas) 
In vitro titration method 
determining colony-forming 
units (5% bovine blood agar) 
USDA SAM 612 (2007) 
[68] 
Vaccination
challenge test in 
swine
9 CFR 113.67 
[68] 
Mannheimia haemolyticaa
(Pasteurella haemolytica)
(cattle respiratory disease) 
In vitro titration method 
determining colony-forming 
units (trypticase soy agar) 
USDA SAM 905 (2009); 
9 CFR 113.68 [69] 
Vaccination
challenge test in 
cattle
-
Chlamydophila felisa
(feline respiratory disease) 
Cell culture– in vitro titration 
method utilizing indirect 
fluorescent antibody staining 
(mouse fibroblasts; MEM) 
USDA SAM 319 (2007); 
9 CFR 113.71 [70] 
- -
Modified Live Viral Vaccines 
Feline calicivirusa
(feline respiratory disease) 
Cell culture– in vitro titration 
method utilizing plaque-forming 
units (Crandall feline kidney 
cells; MEM) 
USDA SAM 306 (2008); 
9 CFR 113.314 [71] 
- -
Feline Rhinotracheitis 
virusa
(feline respiratory disease) 
Cell culture-–in vitro titration 
method utilizing plaque-forming 
units (Crandall feline kidney 
cells; MEM) 
USDA SAM 307 (2008); 
9 CFR 113.315 [72] 
- -
Mareks disease virusa
(poultry neoplastic disease) 
Cell culture– in vitro titration 
method (primary chick embryo 
fibroblasts; M199) 
USDA SAM 406 (2005); 
9 CFR 113.330 [73] 
Vaccination
challenge test in 
chickens
Ph. Eur. 
Monograph 589 
[74] 
Porcine transmissible 
gastroenteritis caused by 
coronavirus TGEVa
(swine infectious diarrhea)
Cell culture– in vitro titration 
method utilizing cytopathic 
effect (swine testicular cells; 
MEM)
USDA SAM 114 (2005) 
[75]
- -
Porcine rotavirusa
(swine infectious diarrhea)
Cell culture-–in vitro method 
utilizing cytopathic effect or 
indirect fluorescent antibody 
technique (Rhesus monkey 
kidney cells; MEM) 
USDA SAM 121 (2005) 
[76] 
- -
Infectious canine hepatitis 
caused by canine 
adenovirus Type 1a
(canine hepatitis) 
Cell culture– in vitro method 
utilizing cytopathic effect 
(primary dog kidney cells; 
MEM)
USDA SAM 304 (2007); 
9 CFR 113.305 [77] 
- -
Canine distemper virusa
(canine viral disease) 
Cell culture– in vitro method 
utilizing cytopathic effect (Vero 
cells; MEM) 
USDA SAM 323 (2007); 
9 CFR 113.306 [78] 
- -
Infectious bursal disease 
virus (IBDV)a
(poultry 
immunosuppressive 
disease)
Cell culture– in vitro titration 
method of tissue culture adapted 
IBDV (primary chick embryo 
FB; M199/F10) 
USDA SAM 408 (2007); 
9 CFR 113.331 [79] 
Immunization 
challenge test in 
chickens
Ph. Eur. 
Monograph 587 
[80]; Thornton 
1976 [81] 
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Vaccine Product 
(Disease) 3Rs Alternative
References for 
Alternative Methods
Traditional Test 
Procedure for 
Which the 
Alternative Method 
is Applicable 
References for 
Traditional
Methods 
Feline panleukopenia 
caused by feline 
parvovirusa
(feline viral disease) 
Cell culture– in vitro titration 
method utilizing indirect 
fluorescent antibody straining 
(Crandall feline kidney cells; 
MEM)
USDA SAM 305 (2007); 
9 CFR 113.304 [82] 
- -
Canine parvovirusa
(canine viral disease) 
USDA SAM 316 (2007); 
9 CFR 113.307 [83] 
- -
Mink distemper virusa
(mink viral disease) 
Embryonated chicken eggs – 
titration of viral plaques on 
chorioallantoic membrane 
(CAM)
USDA SAM 303 (2007); 
9 CFR 113.302 [84] 
Immunization 
challenge test in 
mink 
-
Inactivated Bacterial Vaccines or Bacterins 
Erysipelothrix
rhusiopathiaea (inactivated)
(swine Erysipelas) 
USDA SAM 613 (2009); 
9 CFR 113.119 [85] 
Immunization 
challenge test in 
mice 
USDA SAM 
611 (2008); 
9 CFR 113.119 
[86]  
Escherichia coli bacterinsa
(multispecies gastro-
intestinal)
USDA SAM 620 (K99 
Pilus), 621 (K88 Pilus), 
622 (987P Pilus), and 
623 (F41 Pilus) (2010) 
[87] 
- -
Leptospira interrogans 
Serovar pomona bacterina
(swine, cattle, sheep, goats, 
canine, equine 
leptospirosis) 
USDA SAM 624 (2009); 
9 CFR 113.101 [88] 
USDA SAM 
608 (2008) [89] 
Leptospira interrogans 
Serovar canicola bacterin 
(inactivated,
nonadjuvanted)a, b 
(swine, canine, cattle, 
equine leptospirosis) 
USDA SAM 625 (2009); 
9 CFR 113.103 [90]; Ph. 
Eur. Monograph 447 [91] 
USDA SAM 
609 (2008) [92] 
Leptospira interrogans 
Serovar grippotyphosa 
bacterina
(equine, swine, canine, 
sheep, goats, cattle 
leptospirosis) 
USDA SAM 626 (2009); 
9 CFR 113.104 [93] 
USDA SAM 
617 (2008) [94] 
Leptospira interrogans 
Serovar
icterohaemorrhagiae
bacterina
(swine, canine, cattle, 
equine leptospirosis) 
USDA SAM 627 (2009); 
9 CFR 113.102 [95] 
USDA SAM 
610 (2008) [96] 
Leptospira interrogans 
Serovar hardjo bacterinb
(cattle, sheep, goats, equine 
leptospirosis)
Antigen quantification – in vitro
ELISA
9 CFR 113.105 [97]; Ph. 
Eur. Monograph 1939 
[98]; Hendriksen 2008 [99] 
Immunization 
challenge test in 
hamsterse
-
Clostridium chauvoei;
bovine (black leg) 
In vitro ELISAb (inactivated) USDA Memo 800.104, 
2003 [100] 
Immunization 
followed by live 
spore challenge in 
guinea pigs 
USDA SAM 
220 [101]; Ph. 
Eur. Monograph 
361 [102] 
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Vaccine Product 
(Disease) 3Rs Alternative
References for 
Alternative Methods
Traditional Test 
Procedure for 
Which the 
Alternative Method 
is Applicable 
References for 
Traditional
Methods 
Inactivated Viral Vaccines 
Bovine respiratory viruses 
(BRV, BVD, PI3, BRSV)a
(cattle respiratory disease) 
USDA SAM 120 (1991); 
9 CFR 113.216 (BRV); 
9 CFR 113.115 (BVD) 
[103] 
- -
Feline leukemia virus 
(GP70)a
(feline leukemia) 
USDA SAM 321 (2007); 
9 CFR 113.8 [104] 
Immunization 
challenge
Shibley et al. 
1991 [105] 
Canine coronavirusa
(canine gastrointestinal 
disease)
Antigen quantification – in vitro
ELISA
USDA SAM 322 (2007) 
[106] 
Immunization 
challenge test in 
puppies
-
Newcastle disease virusb
(chicken respiratory 
disease)
Antigen quantificationc – in vitro
ELISA or serology
Ph. Eur. Monograph 870 
[107]; Hendriksen 2007 
[108]; Claassen et al. 2004 
[109] 
Immunization 
challenge in 
chickensf; serology 
-
aAccepted by U.S. regulatory authorities.
bPublished in the European Pharmacopoeia.  
cApplicable after in-house (product-specific) validation. 
dDate is year of last SAM revision.  
eThe European Pharmacopoeia states endpoint is “signs” of disease and not lethality. 
fNot for routine batch release in Europe.
8. Other issues to be addressed to facilitate the replacement of animals in human vaccine potency testing
Workshop participants agreed on the need for global harmonization, which could be accomplished by convening 
meetings and workshops with the various regulatory agencies and international research organizations to discuss 
alternative in vitro vaccine potency testing strategies. The development and implementation of an online, worldwide 
database of available alternative methods was viewed as a potential significant advancement. Workshop participants 
also recognized the importance of standardizing lot-release criteria and encouraging mutual recognition of test 
results among regulatory authorities. This would avoid duplicative testing that results in more animals being used 
and extends the time before products can be released to the public. Participants also recognized the need for 
stepwise advancement in which specific vaccines are prioritized and administrative procedures, such as a reduction 
in the frequency of official control testing, may precede technical strategies based on refinement and replacement 
alternatives. Incentives by regulatory authorities to encourage the implementation of new validated 3Rs approaches 
for potency testing of human vaccines were also viewed as important considerations. Finally, it was considered 
critical for regulators to communicate what is required of a quality control production system to allow development 
of new products without the need for in vivo testing.  
9. Conclusions 
This was the first international workshop held in the United States that focused on the reduction, refinement, and 
replacement of animal use for safety and potency release testing of both human and veterinary vaccines. A key 
accomplishment of the workshop was bringing together experts from industry, academia, and government in the 
areas of potency and safety testing for both human and animal vaccines. Several other recent symposia have sought 
to further the science of the 3Rs as they apply to the use of animals for quality control of biologicals. These 
symposia addressed various aspects of promoting and facilitating the use of non-animal methods for the quality 
control of either human or veterinary biologicals, as well as increasing the understanding and implementation of the 
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consistency approach to the manufacturing of human and veterinary biologics. Several workshops have been 
convened over the past several years that were all dedicated to finding new ways to advance the development and 
implementation of alternative methods for the quality control of human or veterinary biologicals [110, 111, 112]. 
This workshop highlighted the need for basic scientific research, as well as product-specific validation efforts, to 
advance the development, validation, and implementation of alternative methods to replace animals used in potency 
testing of human vaccines. These specific recommendations were considered necessary to address scientific 
knowledge gaps that exist in our understanding of disease processes and/or product-specific information as they 
relate to vaccine function. There was strong agreement among the workshop participants that a thorough in-depth 
understanding of the precise mechanism of protection afforded by a vaccine in the target population is a key first 
step in moving from in vivo to in vitro potency testing.  
Recurring themes that surfaced during the discussions included (1) the need for more open access to methods and 
information such as pharmacopoeial monographs; (2) increased sharing of information among regulators, 
manufacturers, and the scientific community; (3) international harmonization of requirements on test methods and 
specifications (e.g., ICH Q2 R Development and validation of potency assays); (4) recognition that the regulatory 
authorities should encourage the use of 3Rs approaches by various means; and (5) the need for widely available 
validated reference standards, antisera, and reagents. Although specific detailed recommendations from each 
workshop/symposium differed, these same general themes of the need for specific scientific research, the need for 
international harmonization of regulations and specifications, the need for sharing of information, the responsibility 
that regulators have for encouraging the use of alternative methods, and the need for validated reagents were evident 
in the output from each workshop/symposium. By building on and reaffirming these important conclusions and 
recommendations for 3Rs advancement the outcome of this workshop will advance alternative methods for vaccine 
potency testing that will reduce, refine, and replace the use of animals in testing, while maintaining and promoting 
scientific quality and the protection of human health, animal health, and the environment. 
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